Condition category
Circulatory System
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
Heart failure is a condition where the heart does not pump blood around the body as well as it should. Although it is called heart “failure”, the heart is still working, but it might need extra help to make sure it works as well as it can. When someone has been diagnosed with heart failure, they are regularly monitored by their health care team. A blood test for natriuretic peptide (NP) is sometimes used to help diagnose heart failure, and there is some research that shows that monitoring NP may also be useful for monitoring patients with heart failure. It is possible for a doctor or nurse to measure NP from a blood sample themselves with a special machine (a “point of care” test), instead of sending it to a laboratory. This means that they get the result quickly, which would be important if they want to use it to make a decision about whether to change someone’s treatment, or to send them to hospital. The aim of this study is to see if it is practical for a GP or nurse to use the quick blood test to monitor patients with heart failure during their normal care.

Who can participate?
Adults aged 18 and older who have a confirmed diagnoses of heart failure and are currently manged in a primary care setting.

What does the study involve?
Participants are asked to make three extra visits to their GP practice over a year to have the quick blood test, along with some laboratory blood tests and a general check of their heart health. It will be seen if it is practical for the quick blood test to be used when participants come to see a GP or nurse during that year about their heart failure. At the end of the study participants are asked and the GPs and nurses to take part in separate focus groups so that we can find out how they feel about the new test.

What are the possible benefits and risks of participating?
People who take part in the study will get extra monitoring during the study, including the new point of care test, but there is no guarantee that this will directly benefit them. However, all the results of the tests done during the study will be available to their GP, so that they can be used to help care for them. The main risk of the study is the blood sample needed for the new test. This is a standard procedure, which may cause some pain and bruising, but should not result in any other problems.

Where is the study run from?
This study is being run by the Nuffield Department of Primary Care Health Sciences, University of Oxford (UK) and will take place in GP surgeries within the Thames Valley Primary Care Research Network (UK).

When is the study starting and how long is it expected to run for?
October 2016 to May 2019

Who is funding the study?
National Institute for Health Research (UK)

Who is the main contact?
Professor Rafael Perera (Scientific)

Trial website

Contact information



Primary contact

Prof Rafael Perera


Contact details

Nuffield Department of Primary Care Health Sciences
Radcliffe Primary Care 554
Radcliffe Observatory Quarter
Woodstock Road
United Kingdom
+44 (0)1865 2 89220

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Feasibility study of the use of point-of-care NP measurement in primary care in patients with heart failure


Study hypothesis

The primary aim of the study is to determine the variability in natriuretic peptide measurements made using point-of-care technology in heart failure patients in primary care settings, including both between- and within- person variability.

Ethics approval

HSC REC B, 07/11/2017, ref: 234119

Study design

Non-randomised; Both; Design type: Process of Care, Device, Qualitative

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type


Patient information sheet

See additional files


Specialty: Primary care, Primary sub-specialty: Cardiovascular disease; UKCRC code/ Disease: Cardiovascular/ Other forms of heart disease


This is a feasibility study. The intervention is point-of-care NT-proBNP measurement, using a Roche cobas h 232 device, added to current clinical measures at all visits. There is study visits at baseline, 6 and 12 months, as well as point-of-care measurement of NT-proBNP at routine visits for heart failure during the 12 month study period. Following the final study visit at 12 months, focus groups are held separately with patients and participating clinicians to discuss the acceptability of the intervention.practice or patient's home.

Intervention type



Drug names

Primary outcome measure

Between- and within- person variability of point-of-care NP is measured using point-of-care NT-proBNP test results at baseline, 6 months, 12 months, and routine visits for heart failure.

Secondary outcome measures

1. Proportion of planned tests for which results are available is measured using the presence of expected point-of-care NT-proBNP tests results at baseline, 6 months, 12 months, and routine visits for heart failure
2. Proportion of NP tests that GPs report would have changed or did change decision-making process is measured using GP feedback on decision making at baseline, 6 months, 12 months, and routine visits for heart failure
3. Proportion of proposed tests actually carried out is measured using reports of point-of-care test use at baseline, 6 months, 12 months, and routine visits for heart failure
4. Patient acceptability is measured using 5 point Likert score at the 12 month visit
5. Clinician acceptability is measured using 5 point Likert score after the last patient visit at their site
6. Patient views about point-of-care NP testing in primary care is measured using a focus group after their 12 month visit
7. Clinician views about point-of-care NP testing in primary care is measured using a focus group after the last patient visit at their site
8. Recruitment rate is measured using a recruitment log at and before the baseline visit
9. Retention rate is measured using withdrawals before the 6 month and 12 month visits
10. Comparison to lab NT-proBNP measures is measured using point-of-care and lab NT-proBNP results taken at baseline, 6 months and 12 months
11. EQA comparison is measured using test samples at a convenient time for clinical staff
12. EQA precision assessment is measured using test samples at a convenient time for clinical staff

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Participant is willing and able to give informed consent for participation in the study
2. Male or female, aged 18 years or above
3. Confirmed diagnosis of heart failure made by cardiologist and/or echocardiography
4. Currently managed in a primary care setting where the clinician is willing to take part in routine POC NP monitoring

Participant type


Age group




Target number of participants

Planned Sample Size: 27; UK Sample Size: 27

Total final enrolment


Participant exclusion criteria

Participant is considered to be terminally ill or receiving palliative care for another condition only at the time of recruitment.

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Nuffield Department of Primary Care Health Sciences
The University of Oxford
United Kingdom

Sponsor information


University of Oxford

Sponsor details

Clinical Trials & Research Governance
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

National Institute for Health Research

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

National government


United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal

IPD sharing statement:
The datasets generated during the current study will be available upon request from Rafael Perera ( Following publication of the research, fully-anonymised data may be shared with other academic researchers, including those outside the UK, for research purposes only (e.g. for individual patient data meta-analysis). Data will be available for up to 10 years after conclusion of the research, and will be limited to quantitative data (i.e. excluding data from focus groups, for which consent to further sharing will not be available). Consent and ethical approval for this form of sharing will be available, provided that data is not shared further by the recipient, and is used only for the agreed purpose.

Intention to publish date


Participant level data

Available on request

Basic results (scientific)

See additional file (ISRCTN12866009_BasicResults_v1_28Jul2020)

Publication list

Publication citations

Editorial Notes

31/07/2020: The following changes have been made: 1. The basic results of this trial have been uploaded as an additional file. 2. The final enrolment number has been added from the basic results summary. 23/07/2018: The following changes were made to the trial record: 1. The recruitment start date was changed from 01/01/2018 to 21/02/2018. 2. The recruitment end date was changed from 31/03/2018 to 20/03/2018. 3. The overall trial end date was changed from 31/03/2019 to 01/05/2019. 4. The intention to publish date was changed from 30/06/2019 to 31/12/2019. 5. The target number of participants was changed from 40 to 27. 07/12/2017: Uploaded protocol Version 1.8 19 October 2017 (not peer-reviewed).